Panel on Health Services

<u>List of follow-up actions</u> (Position as at 11 January 2019)

Subject	Date of meeting	Follow-up action required	Administration's response
1. Briefing by the Secretary for Food and Health on the Chief Executive's 2017 Policy Address	26 January 2017	 The Administration was requested to provide information on: (a) the increase in public health expenditure in the light of a growing number of elders aged 65 or above under an ageing population; and (b) programmes to promote preventive care for middle-aged adults in primary care setting and the expenditure involved. 	The Administration will provide a response in due course.
2. Proposed extension of Kowloon Psychiatric Observation Unit	24 April 2018	The Administration/the Hospital Authority ("HA") was requested to advise the respective numbers of doctors, psychiatric nurses and allied health staff (with a breakdown by the grades involved), as well as the respective ratios of these healthcare professionals to patients, to support the operation of the Kowloon Psychiatric Observation Unit before and after the new "gazetted" ward commenced operation.	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
3. Briefing by the Secretary for Food and Health on the Chief Executive's 2018 Policy Address	15 October 2018	The Administration was requested to provide a breakdown by expenditure items (including, among others, the subsidized consultation and treatment services) of the \$100 million allocated to subsidize the operation of the Kwai Tsing District Health Centre for a year.	The Administration will provide a response in due course.
4. Preparation for winter surge	19 November 2018	The Administration was requested to provide a response to the views and suggestions given by the Society for Community Organization on seasonal influenza vaccination services as set out in its submission (LC Paper No. CB(2)264/18-19(01)).	The Administration will provide a response in due course.
5. Review findings of means test mechanism for Samaritan Fund and Community Care Fund Medical Assistance Programmes	11 December 2018	The Administration/HA was requested to: (a) advise the factors to be taken into account when determining whether a drug would be included in the Subsidy for Eligible Patients to Purchase Ultra-expensive Drugs (Including Those for Treating Uncommon Disorders) under the Community Care Fund ("the Ultra-expensive Drugs Programme"), and the drugs currently covered under the Programme;	The Administration will provide a response in due course.
		(b) advise the criteria for approving the applications for drug subsidy under the Ultra-expensive Drugs Programme;	

- 3 -

Subject	Date of meeting	Follow-up action required	Administration's response
		(c) in respect of the approved applications for drug subsidy under the Ultra-expensive Drugs Programme, provide a breakdown, by the following ranges, of the amount of patients' contribution to drug cost: under \$100,000; \$100,000 to \$199,999; \$200,000 to \$299,999; \$300,000 to \$399,999; \$400,000 to \$499,999; \$500,000 to \$599,999; \$600,000 to \$699,999; \$700,000 to \$799,999; \$800,000 to \$899,999; \$900,000 to \$1,000,000; and	
		(d) advise the number of applications being rejected under the Samaritan Fund and the Community Care Fund Medical Assistance Programmes due to the reason that the patients concerned did not meet the clinical requirements.	
6. Development of Chinese medicine	17 December 2018	The Administration/HA was requested to: (a) provide a response to the observations and recommendations made by Office of The Ombudsman in respect of the professional development of Chinese medicine pharmacists as set out in paragraphs 6.23, 6.24 and 6.28(11) of	The Administration will provide a response in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
		its Direct Investigation Report on Government's Regulation of Proprietary Chinese Medicine (Chinese version only) released on 13 December 2018;	
		(b) provide a response to the suggestions given by the Hong Kong Chinese Medicine Pharmacists Association on the development of Chinese medicine in its submission to the Panel (LC Paper No. CB(2)473/18-19(01));	
		(c) provide an update in respect of the examination being carried out by the Correctional Services Department in liaison with the Department of Health ("DH") and HA on the recommendation put forward by the jury of a death inquest held by the Coroner's Court in June 2018 that the Administration should consider providing Chinese medicine services as an option for prisoners in prison hospitals; and	
		(d) provide for reference of the Panel the report on the evaluation of HA's Integrated Chinese-Western Medicine Pilot Programme once available.	

Subject	Date of meeting	Follow-up action required	Administration's response
7. Collaboration-referral mechanism between DH and HA in respect of dermatological services provided by DH		1 1	

Council Business Division 2
<u>Legislative Council Secretariat</u>
15 January 2019